September 2021 Top Biopharma Deal: REGENXBIO – AbbVie for RBX-314 for wet AMD, diabetic retinopathy

Oct 7, 2021 | Deal of the Month, Partnership Deals

September 2021 Top Biopharma Deal Upfront
REGENXBIO development and commercialization deal with AbbVie for RGX-314

Highlighted Deal Financial Comps

Date Announced:

September 13, 2021

Total Deal Value:


Upfront Cash:


Upfront Equity:


Option Payments:


Total Milestones:

$1,380M (Dev., Reg., and Sales)


Tiered ex-U.S.

Cost & Profit Split:

50% in U.S.

Deal Synopsis

The Asset:

Phase II RGX-314 for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other chronic retinal diseases.

Deal Structure:

Development and Commercial License

Partnership Features:

Co-Development and co-promotion option.

Deal Details:

  • REGENXBIO granted AbbVie exclusive, worldwide rights to develop and commercialize RGX-314 for the treatment of wet AMD, diabetic retinopathy, and other chronic retinal diseases.
  • REGENXBIO will be responsible for completion of the ongoing trials.
  • AbbVie and REGENXBIO will share costs on additional trials, including the planned second pivotal trial evaluating subretinal delivery for the treatment of wet AMD and future trials.
  • AbbVie will lead the clinical development and commercialization globally.
  • REGENXBIO will participate in U.S. commercialization efforts under a mutually agreed upon plan.
  • REGENXBIO will receive $370M up front and is eligible for up to $1.38B in development, regulatory, and commercial milestones, plus tiered royalties on net sales of RGX-314 outside the U.S. and 50% of profits in the U.S.

Last Month:

Congrats to REGENXBIO and AbbVie for landing the DealForma September 2021 Deal of the Month. The Deal of the Month for August 2021 was RemeGen and Seagen’s HER2 ADC deal with $200M up front for Disitamab Vedotin. Read about it here.

DealForma’s Deal of the Month selection is based on the largest disclosed upfront cash and equity total in partnership deals involving R&D as announced in the month prior to this article. Data for this analysis was compiled using the DealForma biopharma deals database. All data are based on publicly disclosed figures and deal terms.

We invite you to answer interesting questions on biopharma business development and licensing using our data and carefully curated profiles on deals, pipelines, companies, funding, and business executives by visiting to schedule your personalized demo.


Licensing Deals


Funding Rounds




Company Profiles


Other Deals


Drug Sales Figures

All of this by stage, disease indication, modality, target...

More Research by DealForma

Introducing: DealForma plus Tableau

Introducing: DealForma plus Tableau

We are excited to introduce DealForma's new Tableau dashboard integration. High quality data on biopharma deals and funding meets interactive charts and visuals. DealForma customers will have exclusive access to the DealForma chart dashboards built on Tableau right...

Venture & IPO – Medtech – Q1 2023 

Venture & IPO – Medtech – Q1 2023 

The Medtech sector encompasses medical devices, diagnostics, and digital health solutions, playing a crucial role in healthcare. In Q1 2022, the medtech, devices, digital health therapeutics, and wearables sector experienced a strong opening with 95 funding rounds and...